Haloperidol Wzf

Haloperidol Wzf is a prescription medication containing the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in oral dosage form, with strength not specified in the available data. The product is marketed in the European Union and is classified under ATC code N05AD01 as a dopamine D2 receptor antagonist used in psychiatric care. Haloperidol Wzf is indicated for several psychiatric conditions and is prescribed by qualified healthcare professionals.

Haloperidol Wzf is prescribed for the management of several acute and chronic psychiatric disorders.

- Schizophrenia, including maintenance therapy and relapse prevention. - Acute psychotic episodes associated with bipolar disorder or other conditions. - Manic episodes in bipolar I disorder. - Tourette syndrome, particularly when other treatments are insufficient. - Severe agitation or aggression in a hospital setting.

Side effects of haloperidol may vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth. - Constipation. - Blurred vision.

Serious: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe hypotension. - Cardiac arrhythmias, including QT prolongation.

When prescribing Haloperidol Wzf, clinicians consider several safety precautions to minimize risk.

- Assess cardiovascular status, especially for QT prolongation risk. - Monitor for signs of extrapyramidal reactions and adjust dose accordingly. - Use caution in patients with a history of seizures or neuroleptic malignant syndrome. - Evaluate liver and renal function before initiating therapy. - Consider pregnancy and lactation status; use only if benefits outweigh potential risks. - Review patient’s age, as elderly individuals may be more sensitive to side effects.

Haloperidol can interact with other medications, affecting its efficacy or safety profile.

Avoid: - Other dopamine antagonists or antipsychotics (increased risk of additive side effects). - Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors such as ketoconazole (may increase haloperidol levels).

Use with caution: - CYP3A4 inducers like carbamazepine (may reduce effectiveness). - CNS depressants including benzodiazepines or alcohol (enhanced sedation). - Anticholinergic agents (may mask extrapyramidal symptoms).